Editas Medicine
NASDAQ: EDITCambridge, US · Founded 2013 · 5 known investors
Find your way into Editas Medicine
1,565 people in our graph share verified history with the Editas Medicine team — schools, employers, funds. One of them is your warm intro.
Hemant Tanejaunlockedknows Alexandra (Sandra) Glucksmann · together at Massachusetts Institute of Technology (overlapped)
×2knows the team · via Massachusetts Institute of Technology
knows the team · via Flagship Ventures
×3knows the team · via Broad Institute of MIT and Harvard
×2knows the team · via Harvard Medical School
knows the team · via Harvard University
Editas Medicine develops gene editing medicines using CRISPR/Cas9 and CRISPR/Cas12a technology to treat serious diseases including blood disorders, cardiovascular conditions, and cancer. The company focuses on in vivo genome editing approaches and serves patients worldwide with transformative, precision genomic medicines.
Founders & leadership
Editas Medicine was founded in 2013 by Feng Zhang, George Church, Keith Joung, and David Liu.
FZ
Feng ZhanginScientific Founder, Core Member, Broad Institute of MIT and Harvard
GC
George ChurchinScientific Founder, Professor of Genetics, Harvard University and MITGeorge Church is a Professor of Genetics at Harvard University and MIT who developed foundational methods for DNA sequencing, molecular multiplexing, and barcoding in the 1980s; his research contributed to next-generation sequencing technologies and he co-founded Editas Medicine to advance gene editing therapeutics using CRISPR technology.
KJ
Keith JounginScientific Founder, Professor of Pathology, Harvard Medical SchoolFounder and Inventor at Beam Therapeutics
DL
David LiuinScientific Founder, Professor of Chemistry and Chemical Biology, Harvard UniversityDavid Liu is a Professor of Chemistry and Chemical Biology at Harvard University and Vice-Chair of the Faculty at the Broad Institute of Harvard and MIT, where his research focuses on genome editing technologies including base editing and prime editing for treating genetic diseases. He is a Howard Hughes Medical Institute Investigator and has co-founded several biotechnology companies including Editas Medicine, Beam Therapeutics, and Prime Medicine.
KB
Katrine BosleyinCEO2014–2019
VM
Vic MyerinExecutive
AG
AH
Andrew HackinChief Financial Officer2015–2019Andrew Hack is an Executive Officer at Editas Medicine, which develops gene editing medicines using CRISPR technology to treat serious diseases. He has background in healthcare investment and biopharmaceutical company building.
GO
Gilmore O'NeillPresident and Chief Executive Officer
Board
DC
Douglas ColeBoard director
KB
BN
Boris NikolicBoard directorManaging Director at Biomatics Capital
Investors · 5
Reported raises · per SEC filings
Form D private placements$120M disclosed across 1 of 3 rounds · 1900–2015
▶$120MraisedAug 2015 · 43 investors · BiotechnologyRule 506(b)
▶$120MraisedAug 2015 · 43 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Katrine BosleyExecutive Officer, Director
- Vic MyerExecutive Officer
- Alexandra GlucksmannExecutive Officer
- Douglas ColeDirector
- Kevin BittermanDirector
- Andrew HackExecutive Officer
- Boris NikolicDirector
- Alexis BorisyDirector
- Offering amount
- $120M
- Amount sold
- $120M
- First sale
- Aug 2015
- Incorporated
- Corporation, Delaware, 2013
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Valuation · disclosed
Disclosed events$571.2Mvaluation at IPOFeb 2016 · $16.00/share · 424B1
filing ↗Source: SEC prospectus filings, and round valuations the company or its investors disclosed — follow each entry's link for the claim.
Founder mafia
5 people who came through Editas Medicine went on to found or lead other companies.
George ChurchScientific Founder, Professor of Genetics, Harvard University and MITFounded Nebula Genomics +4David R. LiuScientific Founder, Professor of Chemistry and Chemical Biology, Harvard UniversityFounded Prime Medicine +2Alexandra (Sandra) GlucksmannExecutive OfficerFounded Sensorium TherapeuticsMichael C. Bassik, Ph.D.Group LeaderFounded Stylus MedicineShengfang JinVP, Head of Discovery BiologyFounded Ensemtx
Competitors · 2
by search overlap
CRISPR54 shared keywordsCRISPR Therapeutics is a biotechnology company developing gene-based medicines using CRISPR/Cas9 gene-editing technology. It is led by a management team, board of directors, and scientific founders from the biotech and pharmaceutical industries.
Synthego49 shared keywordsSynthego develops CRISPR gene-editing and molecular diagnostics products, including custom CRISPR editors in mRNA or protein formats, base editors, and cell-free protein and RNA production systems. It serves researchers and cell and gene therapy developers in the biotechnology industry.
Companies competing with Editas Medicine for the same Google search keywords, organic and paid, via search-intersection analysis.
Non-dilutive funding · 1 SBIR/STTR award
Federal grants — no equity taken| Agency | Phase | Year | Amount |
|---|---|---|---|
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2015 | $225K |
Source: SBIR.gov award data (U.S. Small Business Administration). SBIR/STTR awards are competitive federal R&D grants and contracts — non-dilutive capital alongside any venture rounds above.
In the news
Frequently asked questions
- What does Editas Medicine do?
- Editas Medicine develops gene editing medicines using CRISPR/Cas9 and CRISPR/Cas12a technology to treat serious diseases including blood disorders, cardiovascular conditions, and cancer. The company focuses on in vivo genome editing approaches and serves patients worldwide with transformative, precision genomic medicines.
- Who founded Editas Medicine?
- Editas Medicine was founded by Feng Zhang, George Church, Keith Joung, David Liu in 2013.
- Who are Editas Medicine's investors?
- Editas Medicine's investors include EcoR1 Capital, Sofinnova Ventures, Deerfield Management Company, Flagship Ventures, Polaris Partners.
- How much funding has Editas Medicine raised?
- Editas Medicine has disclosed $120M raised across 1 of its 3 known rounds.
- Where is Editas Medicine headquartered?
- Editas Medicine is headquartered in Cambridge, US.